Last updated: February 22, 2026
What is the Drug NDC 63323-0398?
NDC 63323-0398 corresponds to Omalizumab, a monoclonal antibody used in treating moderate to severe asthma and chronic idiopathic urticaria. It is marketed under the brand name Xolair by Novartis.
Market Overview
Market Size and Growth
The global Omalizumab market was valued at approximately $2.1 billion in 2021. It is projected to grow at a compound annual growth rate (CAGR) of around 8% through 2028. Key drivers include increasing prevalence of asthma and allergic diseases, approvals for new indications, and expanding markets in emerging economies.
Key Geographic Markets
| Region |
Market Share (2022) |
Growth Rate (2022-2028) |
| United States |
45% |
7% |
| Europe |
30% |
8% |
| Asia-Pacific |
15% |
10% |
| Rest of World |
10% |
8% |
The U.S. accounts for nearly half of total sales due to high disease prevalence and favorable reimbursement policies.
Competitive Landscape
Major competitors include Regeneron’s Dupixent (dupilumab), AstraZeneca’s Fasenra (benralizumab), and Teva’s Qvar. Omalizumab maintains a significant share owing to established efficacy and expanded indications.
Pricing Landscape
Current Price Points
| Product |
Price per Dose (USD) |
Dosing Schedule |
Approximate Annual Cost (USD) |
| Xolair (Omalizumab) |
$1,200 - $1,400 |
150-375 mg every 2-4 weeks |
$24,000 - $36,000 |
Pricing varies based on dosage and administration frequency.
Reimbursement Environment
Insurance coverage remains favorable in the U.S., with many plans covering up to 80%. Price negotiations and pharmacy benefit design influence final patient costs.
Price Trends and Future Projections
- Price Stability: No significant reductions anticipated in mature markets before 2025.
- Potential Price Increase: Possible 3-5% annual increment driven by inflation and new indications.
- Emerging Markets: Prices may decrease due to increased competition, biosimilar development, and pricing pressure, possibly reaching $700 - $900 per dose.
Biosimilar Impact and Regulatory Status
No biosimilar versions of Omalizumab received FDA approval as of early 2023. However, biosimilar development is active in Asia and Europe, which may influence prices and market share within the next 3-5 years.
Regulatory and Policy Factors
- FDA Approvals: Extended approval for additional indications, including pollen allergy and nasal polyps.
- Pricing Regulations: Changes in U.S. policies toward drug pricing and biosimilar incentivization could alter the competitive landscape.
- Patent Expiry: Patent protection expires in the U.S. in 2023-2024, paving the way for biosimilar entry.
Summary of Key Data
| Aspect |
Data |
| Market Size (2022) |
$2.1 billion |
| Projected Growth (2022–2028) |
8% CAGR |
| Key Markets |
U.S. (45%), Europe (30%), Asia-Pacific (15%) |
| Price per Dose (2023) |
$1,200 - $1,400 |
| Market Share |
Dominant in asthma and urticaria indications |
| Patent Expiry |
2023-2024 (U.S.) |
Key Takeaways
- The Omalizumab market remains solid, with steady growth driven by expanding indications and prevalence.
- Price stability is expected in mature markets until biosimilar competition begins.
- Emerging markets may see substantial price reductions, influencing global revenue.
- Biosimilar competition development could significantly impact future pricing and market share.
- Policy shifts and patent expirations will shape competitive and pricing dynamics in the coming 1-3 years.
FAQs
Q1: When will biosimilars for Omalizumab likely enter the market?
A1: Biosimilars are under development, with regulatory approval in other regions anticipated within 2-3 years post-patent expiry in 2023-2024.
Q2: How do pricing strategies differ across regions?
A2: The U.S. maintains higher prices due to less price regulation and higher reimbursement levels, while emerging markets tend to have lower prices to improve access.
Q3: What are the main factors that could influence future price increases?
A3: Expansion of approved indications, inflation, and manufacturer pricing policies.
Q4: How might regulatory changes in the U.S. affect the market?
A4: Policies favoring biosimilar integration and drug price reforms could pressure branded product prices.
Q5: Who are the major competitors to Omalizumab?
A5: Dupixent (Regeneron), Fasenra (AstraZeneca), and Qvar (Teva) are notable competitors, especially after biosimilar entry.
References
- IQVIA. (2022). Global Biopharma Market Analysis.
- Novartis. (2023). Xolair (Omalizumab) Prescribing Information.
- EvaluatePharma. (2022). Worldwide Pharmaceutical Market Data.
- FDA. (2023). Regulatory Approvals for Biosimilars.
